Author of

• 25967

  +

  P3.13 - Targeted Therapy (Not CME Accredited Session) (ID 979)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27701

    +

    P3.13-34 - RET Gene, a New Choice for NSCLC (ID 13654)

    12:00 - 13:30  |  Author(s): Yucong Wang
    • Abstract
    • Slides

    Background
    

    RET gene, accounting for 1-2% of non-small cell lung cancer (NSCLC), has been identified as a novel target molecule which has been reported that could not coexist with other gene mutations such asrejected with the other mutation like KRAS, EGFR, BRAF, MEK1, HER2 and ALK.The emerging targeted agents Cabozantinib and Vandetanib have been recommended by NCCN guidelines for non-small cell lung cancer with RET fusion, based on a series of clinical trials.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We presented a case of lung adenocarcinoma with KIF5B/RET fusion. The patient was a 50-year-old, male, non-smoker, diagnosed as left upper lobe adenocarcinoma lung cancer. We performed a radical resection of pulmonary carcinoma for two years ago. Subsequently,he completed four cycles of chemotherapy with gemcitabine and cisplatin. However, half years later, pleural metastasis made him have to receive systemic treatment but no chemotherapy due to his worse tolerance. We then performed a gene examination with the PCR method using the intraoperative specimen, and finally found positive KIF5B/RET fusion gene. From then on June 10,2017, he started to take cabozantinib for treatment.

    4c3880bb027f159e801041b1021e88e8 Result
    

    He started to take cabozantinib (140 mg orally, once daily) for about nine months. His disease sustained SD during that period (please see Figure 1). No serious adverse events (AEs) except rash (Ⅱ grade) occurred in the whole treatment process.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    We found that the RET gene is a new alternative for lung adenocarcinoma patients without common mutations such as EGFR, ALK, ROS1 and so on. This case report supports a useful reference for the therapy of lung adenocarcinoma patients with RET mutation and may provide a new choice for this kind of NSCLC patients.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.